Oxidative stress-induced JNK/AP-1 signaling is a major pathway involved in selective apoptosis of myelodysplastic syndrome cells by Withaferin-A

Oncotarget

Volumn 8, Issue 44, 2017, Pages 77436-77452

  Oben, Karine Z ^a   Alhakeem, Sara S ^a   McKenna, Mary K ^a   Brandon, Jason A ^a   Mani, Rajeswaran ^b   Noothi, Sunil K ^a   Jinpeng, Liu ^c   Akunuru, Shailaja ^d   Dhar, Sanjit K ^a   Singh, Inder P ^e   Liang, Ying ^a   Wang, Chi ^c   Abdel Latif, Ahmed ^a   Stills, Harold F ^a   St Clair, Daret K ^a   Geiger, Hartmut ^d   Muthusamy, Natarajan ^b   Tohyama, Kaoru ^f   Gupta, Ramesh C ^g   Bondada, Subbarao ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c UNIVERSITY OF KENTUCKY   (United States)

^d CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^e NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

^f KAWASAKI MEDICAL SCHOOL   (Japan)

^g University of Louisville School of Medicine   (United States)

Author keywords

Apoptosis; JNK AP 1 signaling; Myelodysplastic syndrome (MDS); reactive oxygen species (ROS); Withaferin A (WFA)

Indexed keywords

JANUS KINASE; REACTIVE OXYGEN METABOLITE; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTOME; WITHAFERIN A;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; BONE MARROW CELL; CELL DEATH; CELL VIABILITY; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; MYELODYSPLASTIC SYNDROME; MYELODYSPLASTIC SYNDROME CELL LINE; NONHUMAN; OXIDATIVE STRESS; PRIMARY CELL; SIGNAL TRANSDUCTION; TUMOR ENGRAFTMENT; XENOTRANSPLANTATION;

EID: 85030320427     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.20497     Document Type: Article

References (54)

1. Adès L, Itzykson R, Fenaux P. Myelodysplastic syndromes. Lancet. 2014; 383: 2239-52. https://doi.org/10.1016/S0140-6736(13)61901-7
2. Woll PS, Kjallquist U, Chowdhury O, Doolittle H, Wedge DC, Thongjuea S, Erlandsson R, Ngara M, Anderson K, Deng Q, Mead AJ, Stenson L, Giustacchini A, et al. Myelodysplastic syndromes are propagated by rare and distinct human cancer stem cells in vivo. Cancer Cell. 2014; 25: 794-808. https://doi.org/10.1016/j.ccr.2014.03.036
3. Santini V. Anemia as the main manifestation of myelodysplastic syndromes. Semin Hematol. 2015; 52: 348-56 https://doi.org/10.1053/j.seminhematol.2015.06.002
4. Shukron O, Vainstein V, Kündgen A, Germing U, Agur Z. Analyzing transformation of myelodysplastic syndrome to secondary acute myeloid leukemia using a large patient database. Am J Hematol. 2012; 87: 853-60. https://doi. org/10.1002/ajh.23257
5. Quintas-Cardama A, Daver N, Kim H, Dinardo C, Jabbour E, Kadia T, Borthakur G, Pierce S, Shan J, Cardenas-Turanzas M, Cortes J, Ravandi F, Wierda W, et al. A prognostic model of therapy-related myelodysplastic syndrome for predicting survival and transformation to acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2014; 14: 401-10. https://doi.org/10.1016/j. clml.2014.03.001
6. Bejar R, Steensma DP. Recent developments in myelodysplastic syndromes. Blood. 2014; 124: 2793-803. https://doi.org/10.1182/blood-2014-04-522136
7. Derissen EJ, Beijnen JH, Schellens JH. Concise drug review: azacitidine and decitabine. Oncologist. 2013; 18: 619-24. https://doi.org/10.1634/theoncologist.2012-0465
8. Gohring G, Giagounidis A, Busche G, Kreipe HH, Zimmermann M, Hellstrom-Lindberg E, Aul C, Schlegelberger B. Patients with del(5q) MDS who fail to achieve sustained erythroid or cytogenetic remission after treatment with lenalidomide have an increased risk for clonal evolution and AML progression. Ann Hematol. 2010; 89: 365-74. https://doi.org/10.1007/s00277-009-0846-z
9. Prebet T, Gore SD, Esterni B, Gardin C, Itzykson R, Thepot S, Dreyfus F, Rauzy OB, Recher C, Ades L, Quesnel B, Beach CL, Fenaux P, et al. Outcome of highrisk myelodysplastic syndrome after azacitidine treatment failure. J Clin Oncol. 2011; 29: 3322-7. https://doi. org/10.1200/jco.2011.35.8135
10. Jabbour EJ, Garcia-Manero G, Strati P, Mishra A, Al Ali NH, Padron E, Lancet J, Kadia T, Daver N, O'Brien S, Steensma DP, Sekeres MA, Gore SD, et al. Outcome of patients with low-risk and intermediate-1-risk myelodysplastic syndrome after hypomethylating agent failure: a report on behalf of the MDS Clinical Research Consortium. Cancer. 2015; 121: 876-82. https://doi. org/10.1002/cncr.29145
11. Bhatt VR, Steensma DP. Hematopoietic cell transplantation for myelodysplastic syndromes. J Oncol Pract. 2016; 12: 786-92. https://doi.org/10.1200/jop.2016.015214
12. Greenwell M, Rahman PK. Medicinal plants: their use in anticancer treatment. Int J Pharm Sci Res. 2015; 6: 4103-12 https://doi.org/10.13040/ijpsr.0975-8232.6(10).4103-12
13. Vyas AR, Singh SV. Molecular targets and mechanisms of cancer prevention and treatment by withaferin a, a naturally occurring steroidal lactone. AAPS J. 2014; 16: 1-10. https://doi.org/10.1208/s12248-013-9531-1
14. McKenna MK, Gachuki BW, Alhakeem SS, Oben KN, Rangnekar VM, Gupta RC, Bondada S. Anti-cancer activity of withaferin A in B-cell lymphoma. Cancer Biol Ther. 2015; 16: 1088-98. https://doi.org/10.1080/15384047.201 5.1046651
15. Munagala R, Kausar H, Munjal C, Gupta RC. Withaferin A induces p53-dependent apoptosis by repression of HPV oncogenes and upregulation of tumor suppressor proteins in human cervical cancer cells. Carcinogenesis. 2011; 32: 1697-705. https://doi.org/10.1093/carcin/bgr192
16. Wegrzyn J, Lam JC, Karsan A. Mouse models of myelodysplastic syndromes. Leuk Res. 2011; 35: 853-62. https://doi.org/10.1016/j.leukres.2011.03.007
17. Benito AI, Bryant E, Loken MR, Sale GE, Nash RA, John Gass M, Deeg HJ. NOD/SCID mice transplanted with marrow from patients with myelodysplastic syndrome (MDS) show long-term propagation of normal but not clonal human precursors. Leuk Res. 2003; 27: 425-36
18. Drexler HG, Dirks WG, Macleod RA. Many are called MDS cell lines: one is chosen. Leuk Res. 2009; 33: 1011-6. https://doi.org/10.1016/j.leukres.2009.03.005
19. Matsuoka A, Tochigi A, Kishimoto M, Nakahara T, Kondo T, Tsujioka T, Tasaka T, Tohyama Y, Tohyama K. Lenalidomide induces cell death in an MDS-derived cell line with deletion of chromosome 5q by inhibition of cytokinesis. Leukemia. 2010; 24: 748-55. https://doi. org/10.1038/leu.2009.296
20. Rhyasen GW, Wunderlich M, Tohyama K, Garcia-Manero G, Mulloy JC, Starczynowski DT. An MDS xenograft model utilizing a patient-derived cell line. Leukemia. 2014; 28: 1142-5. https://doi.org/10.1038/leu.2013.372
21. Pedersen-Bjergaard J, Pedersen M, Roulston D, Philip P. Different genetic pathways in leukemogenesis for patients presenting with therapy-related myelodysplasia and therapy-related acute myeloid leukemia. Blood. 1995; 86: 3542-52
22. Pedersen-Bjergaard J, Andersen MT, Andersen MK. Genetic pathways in the pathogenesis of therapy-related myelodysplasia and acute myeloid leukemia. Hematology Am Soc Hematol Educ Program. 2007; 2007: 392-7. https://doi.org/10.1182/asheducation-2007.1.392
23. Smith SM, Le Beau MM, Huo D, Karrison T, Sobecks RM, Anastasi J, Vardiman JW, Rowley JD, Larson RA. Clinicalcytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series. Blood. 2003; 102: 43-52. https://doi. org/10.1182/blood-2002-11-3343
24. Duong VH, Komrokji RS, List AF. Efficacy and safety of lenalidomide in patients with myelodysplastic syndrome with chromosome 5q deletion. Ther Adv Hematol. 2012; 3: 105-16. https://doi.org/10.1177/2040620711435659
25. Wang Y, Probin V, Zhou D. Cancer therapy-induced residual bone marrow injury-mechanisms of induction and implication for therapy. Curr Cancer Ther Rev. 2006; 2: 271-9
26. Breccia M, Alimena G. NF-kappaB as a potential therapeutic target in myelodysplastic syndromes and acute myeloid leukemia. Expert Opin Ther Targets. 2010; 14: 1157-76. https://doi.org/10.1517/14728222.2010.522570
27. Gottlieb E, Armour SM, Harris MH, Thompson CB. Mitochondrial membrane potential regulates matrix configuration and cytochrome c release during apoptosis. Cell Death Differ. 2003; 10: 709-17. https://doi.org/10.1038/sj.cdd.4401231
28. Perelman A, Wachtel C, Cohen M, Haupt S, Shapiro H, Tzur A. JC-1: alternative excitation wavelengths facilitate mitochondrial membrane potential cytometry. Cell Death Dis. 2012; 3: e430. http://www.nature.com/cddis/journal/v3/n11/suppinfo/cddis2012171s1.html
29. Porter AG, Janicke RU. Emerging roles of caspase-3 in apoptosis. Cell Death Differ. 1999; 6: 99-104. https://doi. org/10.1038/sj.cdd.4400476
30. Dhanasekaran DN, Reddy EP. JNK signaling in apoptosis. Oncogene. 2008; 27: 6245-51. https://doi.org/10.1038/onc.2008.301
31. Circu ML, Aw TY. Reactive oxygen species, cellular redox systems, and apoptosis. Free Radic Biol Med. 2010; 48: 749-62 https://doi.org/10.1016/j.freeradbiomed.2009.12.022
32. Raman M, Chen W, Cobb MH. Differential regulation and properties of MAPKs. Oncogene. 2007; 26: 3100-12. https://doi.org/10.1038/sj.onc.1210392
33. Wu Z, Wu J, Jacinto E, Karin M. Molecular cloning and characterization of human JNKK2, a novel Jun NH2-terminal kinase-specific kinase. Mol Cell Biol. 1997; 17: 7407-16
34. Sharma SC, Richards JS. Regulation of AP1 (Jun/Fos) factor expression and activation in ovarian granulosa cells. Relation of JunD and Fra2 to terminal differentiation. J Biol Chem. 2000; 275: 33718-28. https://doi.org/10.1074/jbc. M003555200
35. Whitfield J, Neame SJ, Paquet L, Bernard O, Ham J. Dominant-negative c-Jun promotes neuronal survival by reducing BIM expression and inhibiting mitochondrial cytochrome c release. Neuron. 2001; 29: 629-43
36. Boonstra J, Post JA. Molecular events associated with reactive oxygen species and cell cycle progression in mammalian cells. Gene. 2004; 337: 1-13. https://doi. org/10.1016/j.gene.2004.04.032
37. Zhang T, Inesta-Vaquera F, Niepel M, Zhang J, Ficarro SB, Machleidt T, Xie T, Marto JA, Kim N, Sim T, Laughlin JD, Park H, LoGrasso PV, et al. Discovery of potent and selective covalent inhibitors of JNK. Chem Biol. 2012; 19: 140-54. https://doi.org/10.1016/j.chembiol.2011.11.010
38. Bennett BL, Sasaki DT, Murray BW, O'Leary EC, Sakata ST, Xu W, Leisten JC, Motiwala A, Pierce S, Satoh Y, Bhagwat SS, Manning AM, Anderson DW. SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase. Proc Natl Acad Sci U S A. 2001; 98: 13681-6. https://doi. org/10.1073/pnas.251194298
39. Li Y, Deutzmann A, Choi PS, Fan AC, Felsher DW. BIM mediates oncogene inactivation-induced apoptosis in multiple transgenic mouse models of acute lymphoblastic leukemia. Oncotarget. 2016; 7: 26926-34. https://doi. org/10.18632/oncotarget.8731
40. Aguilo N, Uranga S, Marinova D, Martin C, Pardo J. Bim is a crucial regulator of apoptosis induced by Mycobacterium tuberculosis. Cell Death Dis. 2014; 5: e1343. https://doi. org/10.1038/cddis.2014.313
41. Zong WX, Lindsten T, Ross AJ, MacGregor GR, Thompson CB. BH3-only proteins that bind pro-survival Bcl-2 family members fail to induce apoptosis in the absence of Bax and Bak. Genes Dev. 2001; 15: 1481-6. https://doi.org/10.1101/gad.897601
42. Szatrowski TP, Nathan CF. Production of large amounts of hydrogen peroxide by human tumor cells. Cancer Res. 1991; 51: 794-8
43. Trachootham D, Zhou Y, Zhang H, Demizu Y, Chen Z, Pelicano H, Chiao PJ, Achanta G, Arlinghaus RB, Liu J, Huang P. Selective killing of oncogenically transformed cells through a ROS-mediated mechanism by betaphenylethyl isothiocyanate. Cancer Cell. 2006; 10: 241-52. https://doi.org/10.1016/j.ccr.2006.08.009
44. Trachootham D, Alexandre J, Huang P. Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? Nat Rev Drug Discov. 2009; 8: 579-91
45. Miao L, Holley AK, Zhao Y, St Clair WH, St Clair DK. Redox-mediated and ionizing-radiation-induced inflammatory mediators in prostate cancer development and treatment. Antioxid Redox Signal. 2014; 20: 1481-500. https://doi.org/10.1089/ars.2013.5637
46. Liou GY, Storz P. Reactive oxygen species in cancer. Free Radic Res. 2010; 44: 479-96. https://doi. org/10.3109/10715761003667554
47. Goncalves AC, Cortesao E, Oliveiros B, Alves V, Espadana AI, Rito L, Magalhaes E, Lobao MJ, Pereira A, Nascimento Costa JM, Mota-Vieira L, Sarmento-Ribeiro AB. Oxidative stress and mitochondrial dysfunction play a role in myelodysplastic syndrome development, diagnosis, and prognosis: a pilot study. Free Radic Res. 2015; 49: 1081-94 https://doi.org/10.3109/10715762.2015.1035268
48. Bowen D, Wang L, Frew M, Kerr R, Groves M. Antioxidant enzyme expression in myelodysplastic and acute myeloid leukemia bone marrow: further evidence of a pathogenetic role for oxidative stress? Haematologica. 2003; 88: 1070-2
49. Zhang H, Fang H, Wang K. Reactive oxygen species in eradicating acute myeloid leukemic stem cells. Stem Cell Investig. 2014; 1: 13. https://doi.org/10.3978/j. issn.2306-9759.2014.04.03
50. Okamoto S, Tsujioka T, Suemori S, Kida J, Kondo T, Tohyama Y, Tohyama K. Withaferin A suppresses the growth of myelodysplasia and leukemia cell lines by inhibiting cell cycle progression. Cancer Sci. 2016; 107: 1302-14. https://doi.org/10.1111/cas.12988
51. Oben KZ, Gachuki BW, Alhakeem SS, McKenna MK, Liang Y, St Clair DK, Rangnekar VM, Bondada S. Radiation induced apoptosis of murine bone marrow cells is independent of early growth response 1 (EGR1). PLoS One. 2017; 12: e0169767. https://doi.org/10.1371/journal. pone.0169767
52. Carvalho BS, Irizarry RA. A framework for oligonucleotide microarray preprocessing. Bioinformatics. 2010; 26: 2363-7 https://doi.org/10.1093/bioinformatics/btq431
53. Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, Smyth GK. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015; 43: e47. https://doi.org/10.1093/nar/gkv007
54. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, Mesirov JP. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005; 102: 15545-50. https://doi.org/10.1073/pnas.0506580102